Novartis CEO sees no need for big takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Bristol-Myers Squibb (BMY) Granted European Commission Approval Opdivo (Nivolumab)
June 2, 2017 5:06 PM EDTBristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Todays decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for... More
Bristol-Myers Squibb (BMY) & Seattle Genetics (SGEN) Announce Expanded Collaboration to Evaluate Combination of Opdivo (Nivolumab) & ADCETRIS (Brentuximab Vedotin) in Phase 3 Clinical Trial
June 2, 2017 6:03 AM EDTBristol-Myers Squibb Company (NYSE: BMY) and Seattle Genetics, Inc. (Nasdaq:... More
